Median progression free survival ( PFS ) for @ patients allocated XP plus simvastatin was @ months ( @ % confidence interval ( CI ) @-@ @ ) compared with @ months ( @ % CI @-@ @ ) for @ patients who were allocated to XP plus placebo ( hazard ratio @ , @ % CI @-@ @ ; p = @ ) .